Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 4/20 | 0.45 |
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | DDX3X | O00571 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3770263 | 0.88 | SLC7A5 (0.47) | ADRB2SLC7A5MAOAMAOBGRIA2 | |
| SCHEMBL3770259 | 0.88 | SLC7A5 (0.47) | ADRB2SLC7A5MAOAMAOBGRIA2 | |
| SCHEMBL10442378 | 0.84 | LOXL2 (0.46) | SLC7A5ALDH1A1GRIA2NOS3NOS1 | |
| SCHEMBL13699436 | 0.83 | GRIA2 (0.50) | SLC7A5ALDH1A1GRIA2NOS2 | |
| SCHEMBL15179166 | 0.83 | CTSB (0.48) | ALDH1A1MAOBPOLB | |
| SCHEMBL24711924 | 0.81 | SLC1A1 (0.49) | ALDH1A1MAOB | |
| SCHEMBL12668877 | 0.81 | SLC1A1 (0.49) | ALDH1A1MAOB | |
| SCHEMBL14898396 | 0.81 | PNMT (0.51) | ALDH1A1 | |
| SCHEMBL16574567 | 0.81 | CTSB (0.48) | SLC7A5ALDH1A1POLB | |
| SCHEMBL14942915 | 0.81 | PNMT (0.51) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809278-B2 | Cyclic tetrapeptides | UNIVERSITY OF KANSAS (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809278-B2 | Cyclic tetrapeptides | UNIVERSITY OF KANSAS (US) | 2014-08-19 | — | — | US | disclosed |
| US-20110190212-A1 | CYCLIC TETRAPEPTIDES | UNIVERSITY OF KANSAS (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190212-A1 | CYCLIC TETRAPEPTIDES | UNIVERSITY OF KANSAS (US) | 2011-08-04 | — | — | US | disclosed |
| WO-2010006267-A2 | CYCLIC TETRAPEPTIDES | UNIVERSITY OF KANSAS (US) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190212-A1 | CYCLIC TETRAPEPTIDES | OPRK1, OPRL1, OPRD1 | ADRB2 2103/4885SLC7A5 625/4885ALDH1A1 4554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.